Tasigna Lawsuits in 2026: Atherosclerosis and Heart Injury Claims

The Tasigna federal multidistrict litigation (MDL No. 3006) is the main forum for claims that Novartis's leukemia drug caused atherosclerosis-related injuries. With 36 of 39 cases still pending as of April 2025 and no announced global settlement, this guide explains the allegations, the case status, and who may still qualify.

What Is the Tasigna Litigation?

Tasigna (nilotinib) is Novartis's prescription drug for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), a blood cancer. It is a tyrosine kinase inhibitor (TKI) — a class that blocks enzymes cancer cells need to grow — approved by the FDA in 2007. From the 2010s on, patients who had taken the drug sued, alleging severe atherosclerotic injuries: hardening and narrowing of arteries that can cause heart attacks, strokes and limb-threatening circulation problems. The federal cases were centralized on August 10, 2021, as multidistrict litigation (MDL) No. 3006 before Judge Roy B. Dalton Jr. in the Middle District of Florida — individual cases coordinated pretrial, not a class action.

Key Figures in the 2026 Update

  • 2007: the year the FDA approved Tasigna (nilotinib) for Ph+ CML (aboutlawsuits.com).
  • 2013: Health Canada warned of Tasigna atherosclerosis risk; Novartis warned Canadian doctors but added no comparable U.S. warning (drugwatch.com, May 8, 2026).
  • August 10, 2021: the JPML centralized the federal Tasigna cases as MDL No. 3006 in the Middle District of Florida, over Novartis's objection (schmidtandclark.com).
  • 39 / 36: as of April 1, 2025, 39 MDL cases filed, 36 still pending; no global settlement announced (drugwatch.com; schmidtandclark.com).
  • $390 million: Novartis's November 2015 settlement with the U.S. Attorney's Office ($370M civil + $20M forfeiture) ended a whistleblower kickback case involving Exjade, Myfortic, TOBI, Tasigna and Gleevec — not Tasigna injury claims (schmidtandclark.com).

The Failure-to-Warn Allegations

The lawsuits allege Novartis failed to warn American patients and doctors that Tasigna could cause severe atherosclerotic injuries, while concealing what it knew. Plaintiffs cite a documented sequence: in 2010, investigators reportedly warned Novartis of growing atherosclerosis-related conditions in Tasigna patients, and in 2013, after Health Canada investigated, Novartis warned Canadian doctors and patients — yet added no similar warning to U.S. labeling. These are allegations, not court findings: no court has ruled on Novartis's liability, and the cases remain in pretrial proceedings. Injuries named include atherosclerosis, peripheral arterial disease, coronary artery disease, heart attack, stroke, amputation and death.

The 2018 Individual Settlements

Novartis has offered no blanket settlement. Two individual cases settled in 2018 with undisclosed terms. Dennis and Lori McWilliams settled in August 2018 — the first known Tasigna severe-side-effects settlement. That month Kristi Lauris's wrongful-death case also settled, approved in November 2018: her husband Dainis was prescribed Tasigna in October 2012, developed peripheral arterial occlusive disease within a year, suffered a stroke after surgery and died. The amount was sealed (the case involved a minor) and structured as a 7-year guaranteed annuity toward the daughter's tuition and living costs. Compensation varies widely by case and most settlements are confidential.

Who Benefits From This — and Who Does Not

Who benefits. (1) CML patients who took Tasigna and later suffered atherosclerosis-related injuries — heart attack, stroke, peripheral arterial disease or amputation — how: they may have an individual claim in MDL No. 3006, where consolidated discovery and shared experts make complex drug cases feasible. (2) Families of Tasigna patients who died from alleged arterial injuries — how: spouses and children may pursue wrongful-death claims, as in the settled Lauris case, within deadlines. (3) Readers researching drug-injury and toxic-exposure mass torts — how: comparing active dockets clarifies timelines and proof burdens, as in our benzene and AFFF guides.

Who does not benefit. (1) Tasigna patients with no arterial or heart injury — the litigation covers atherosclerosis and related injuries, not ordinary side effects, so taking Tasigna alone is not a claim. (2) Patients who took a different TKI, such as Gleevec — the allegations are specific to Tasigna/nilotinib. (3) Claims whose statute of limitations expired — many states allow only two to three years from injury or discovery, so a late evaluation can mean no case even with a genuine injury.

How a Tasigna Claim Moves Through the MDL

A claim starts as an individual lawsuit, filed by the plaintiff's attorney and transferred into MDL No. 3006: shared discovery — Novartis documents, depositions, causation experts — then bellwether trial selection or settlement talks. To begin: (1) assemble medical records proving Tasigna use and the arterial or cardiac injury, with dates; (2) build a timeline showing the drug was taken before the injury appeared; (3) get a free, no-obligation case review from a drug-injury mass-tort lawyer; and (4) confirm your state's deadline, which runs from injury or discovery, not the MDL's schedule.

Frequently Asked Questions

Who benefits from the Tasigna lawsuits?

People who took Tasigna for chronic myeloid leukemia and later suffered atherosclerosis-related injuries — heart attack, stroke, peripheral arterial disease, coronary artery disease, amputation — may have an individual claim in MDL No. 3006. Families of patients who died from such injuries may bring wrongful-death claims. No class action or public claim form exists.

Who does not benefit — am I eligible if I took Tasigna but had no heart or artery problems?

No. The litigation covers atherosclerosis and related cardiovascular injuries, not ordinary side effects or simply taking the drug — without an arterial or cardiac injury there is no claim. Claims about other drugs, such as Gleevec, fall outside it, and expired deadlines bar late claims.

How do I start a Tasigna claim?

Gather medical records of Tasigna use and the arterial or cardiac injury, with dates; build a timeline showing the drug preceded the injury; get a free case review from a drug-injury mass-tort lawyer; and confirm your state's filing deadline, which usually runs from the injury or its discovery.

Has Novartis settled the Tasigna injury cases?

There is no announced global settlement, and no court has ruled on Novartis's liability. Two individual cases settled confidentially in 2018 — McWilliams and Lauris's wrongful-death case — with amounts undisclosed. Compensation varies widely by case and most settlements are confidential.

What injuries are named in Tasigna claims?

Atherosclerosis, peripheral arterial disease, coronary artery disease, circulatory problems of the legs, arms, heart or brain, embolic occlusion, heart attack, stroke, amputation and death — injuries tied to the narrowing and blocking of arteries.

More plain-language mass-tort explainers: https://www.youtube.com/@problemsolved-x3m.

Disclaimer: This article is for general information only and is not legal or medical advice. Claims involve individual facts and strict filing deadlines — consult a qualified attorney and your doctor about your own situation.

Watch on YouTube

Problem Solved on YouTube